The major goal of diabetes treatment is to reduce macrovascular complications, microvascular complications, and death.15 Although both metformin and sodium-glucose co-transporter two showed cardiovascular mortality reduction.16 However, no face-to-face meta-analysis was conducted.17 The present meta-analysis showed that SGLT-2 inhibitors had lower rates of heart failure (odd ratio, 1.51, 95% CI, 1.10-2.08) and myocardial infarction (odd ratio, 1.45, 95% CI, 1.08-1.96) than metformin with a similar rate of stroke (odd ratio, 1.03, 95% CI, 0.66-1.61). The gene discussed is SLC5A2; the disease is heart failure.